$ACAD
ACADIA PHARMACEUTICALS INC

2021 Q3 Form 10-Q Financial Statement

#000156459021055347 Filed on November 09, 2021

View on sec.gov

Income Statement

Concept 2021 Q3 2020 Q3
Revenue $131.6M $120.6M
YoY Change 9.15% 27.48%
Cost Of Revenue $6.682M $4.800M
YoY Change 39.21% 98.68%
Gross Profit $127.9M $118.6M
YoY Change 7.89% 28.64%
Gross Profit Margin 97.2% 98.34%
Selling, General & Admin $81.67M $81.60M
YoY Change 0.08% 12.24%
% of Gross Profit 63.84% 68.82%
Research & Development $58.57M $120.1M
YoY Change -51.24% 91.85%
% of Gross Profit 45.78% 101.29%
Depreciation & Amortization $985.0K $710.0K
YoY Change 38.73% 9.23%
% of Gross Profit 0.77% 0.6%
Operating Expenses $140.2M $201.7M
YoY Change -30.48% 49.08%
Operating Profit -$12.31M -$83.13M
YoY Change -85.2% 83.02%
Interest Expense $129.0K $1.200M
YoY Change -89.25% -50.66%
% of Operating Profit
Other Income/Expense, Net $383.0K -$200.0K
YoY Change -291.5% -126.77%
Pretax Income -$14.79M -$84.90M
YoY Change -82.58% 100.98%
Income Tax -$332.0K -$200.0K
% Of Pretax Income
Net Earnings -$14.46M -$84.66M
YoY Change -82.92% 101.68%
Net Earnings / Revenue -10.98% -70.21%
Basic Earnings Per Share -$0.09
Diluted Earnings Per Share -$89.98K -$535.7K
COMMON SHARES
Basic Shares Outstanding 160.7K
Diluted Shares Outstanding 160.7K

Balance Sheet

Concept 2021 Q3 2020 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $540.3M $644.4M
YoY Change -16.16% -5.76%
Cash & Equivalents $100.4M $452.4M
Short-Term Investments $445.7M $192.1M
Other Short-Term Assets $24.62M $30.00M
YoY Change -17.93% 40.19%
Inventory $14.34M $7.979M
Prepaid Expenses
Receivables $60.70M $46.30M
Other Receivables $972.0K $1.500M
Total Short-Term Assets $640.9M $730.2M
YoY Change -12.23% -1.63%
LONG-TERM ASSETS
Property, Plant & Equipment $68.61M $56.70M
YoY Change 21.01% 329.55%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $2.373M $7.300M
YoY Change -67.49% 216.43%
Total Long-Term Assets $76.76M $65.50M
YoY Change 17.18% 181.28%
TOTAL ASSETS
Total Short-Term Assets $640.9M $730.2M
Total Long-Term Assets $76.76M $65.50M
Total Assets $717.7M $795.7M
YoY Change -9.81% 3.93%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $7.722M $3.500M
YoY Change 120.63% 1.63%
Accrued Expenses $80.50M $88.39M
YoY Change -8.93% 37.46%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $88.22M $91.90M
YoY Change -4.01% 35.66%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $62.50M $48.90M
YoY Change 27.81% 2149.31%
Total Long-Term Liabilities $62.50M $48.90M
YoY Change 27.81% 2149.31%
TOTAL LIABILITIES
Total Short-Term Liabilities $88.22M $91.90M
Total Long-Term Liabilities $62.50M $48.90M
Total Liabilities $150.7M $140.8M
YoY Change 7.04% 84.54%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $567.0M $654.9M
YoY Change
Total Liabilities & Shareholders Equity $717.7M $795.7M
YoY Change -9.81% 3.93%

Cashflow Statement

Concept 2021 Q3 2020 Q3
OPERATING ACTIVITIES
Net Income -$14.46M -$84.66M
YoY Change -82.92% 101.68%
Depreciation, Depletion And Amortization $985.0K $710.0K
YoY Change 38.73% 9.23%
Cash From Operating Activities -$17.06M -$22.79M
YoY Change -25.13% 20.9%
INVESTING ACTIVITIES
Capital Expenditures $0.00 -$1.720M
YoY Change -100.0% 2050.0%
Acquisitions
YoY Change
Other Investing Activities -$156.3M $154.7M
YoY Change -201.03% 1447.2%
Cash From Investing Activities -$156.3M $153.0M
YoY Change -202.17% 1442.34%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.066M 11.71M
YoY Change -90.9% -96.34%
NET CHANGE
Cash From Operating Activities -17.06M -22.79M
Cash From Investing Activities -156.3M 153.0M
Cash From Financing Activities 1.066M 11.71M
Net Change In Cash -172.3M 141.9M
YoY Change -221.42% -54.37%
FREE CASH FLOW
Cash From Operating Activities -$17.06M -$22.79M
Capital Expenditures $0.00 -$1.720M
Free Cash Flow -$17.06M -$21.07M
YoY Change -19.01% 12.25%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
acad Obligation Expiration Year
ObligationExpirationYear
2021
us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
true
CY2021Q3 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#AccountsPayableAndAccruedLiabilitiesCurrent
CY2020Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#AccountsPayableAndAccruedLiabilitiesCurrent
CY2021Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
57677000
CY2021Q3 us-gaap Assets
Assets
717673000
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
80496000
CY2021Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
5770000
CY2021Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2373000
CY2021Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
7722000
CY2021Q3 us-gaap Liabilities Current
LiabilitiesCurrent
88218000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-108678000
us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
100808000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1671000
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
11403000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
17853000
acad Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-587000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
737000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
458122000
us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
44280000
us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
926000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
62870000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-4000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
263655000
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-281000
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
44280000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
10563000
us-gaap Increase Decrease In Accounts Receivable And Other Operating Assets
IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets
-653000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
5588000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
309467000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
62870000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
627009000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
699135000
CY2021Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-39000
CY2020Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-971000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-37000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
212000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
566955000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
654867000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
6000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-231388000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
100410000
acad Increase Decrease In Operating Lease Assets
IncreaseDecreaseInOperatingLeaseAssets
-2863000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-50000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-3751000
CY2021Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
65827000
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
452352000
CY2020Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
5770000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
458122000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
18569000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
19704000
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
21372000
CY2021Q3 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
6670000
CY2021Q3 us-gaap Inventory Net
InventoryNet
14336000
CY2021Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
21783000
CY2021Q3 acad Accrued Clinical Development Services Current
AccruedClinicalDevelopmentServicesCurrent
20930000
CY2020Q4 acad Accrued Clinical Development Services Current
AccruedClinicalDevelopmentServicesCurrent
28380000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
18969000
CY2021Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
8150000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
5087000
CY2020Q4 acad Accrued Sales Allowances Current
AccruedSalesAllowancesCurrent
14115000
CY2021Q3 acad Accrued Branded Prescription Drug Fees Current
AccruedBrandedPrescriptionDrugFeesCurrent
1959000
CY2020Q4 acad Accrued Branded Prescription Drug Fees Current
AccruedBrandedPrescriptionDrugFeesCurrent
1845000
CY2021Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2758000
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
80496000
CY2020Q4 acad Debt Securities And Equity Securities Fv Ni Amortized Cost
DebtSecuritiesAndEquitySecuritiesFvNiAmortizedCost
305899000
CY2020Q4 acad Debt Securities And Equity Securities Fv Ni Unrealized Gains
DebtSecuritiesAndEquitySecuritiesFvNiUnrealizedGains
74000
CY2020Q4 acad Debt Securities And Equity Securities Fv Ni Unrealized Losses
DebtSecuritiesAndEquitySecuritiesFvNiUnrealizedLosses
43000
CY2020Q4 acad Debt Securities And Equity Securities Fv Ni
DebtSecuritiesAndEquitySecuritiesFvNi
305930000
CY2021Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
32
CY2020Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
24
CY2021Q3 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
257337000
CY2021Q3 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
40000
CY2021Q3 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue
257337000
CY2021Q3 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss
40000
CY2020Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
169353000
CY2020Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
43000
CY2020Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue
169353000
CY2020Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss
43000
CY2021Q2 acad Number Of Motions
NumberOfMotions
5
us-gaap Lessee Operating Lease Description
LesseeOperatingLeaseDescription
The Company leases facilities and certain equipment under noncancelable operating leases with remaining lease terms of 0.3 years to 9.7 years, some of which include options to extend for up to two five-year terms.
us-gaap Lessee Operating Lease Option To Extend
LesseeOperatingLeaseOptionToExtend
some of which include options to extend for up to two five-year terms.
CY2021Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
2014000
CY2020Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
1835000
us-gaap Operating Lease Cost
OperatingLeaseCost
7016000
us-gaap Operating Lease Cost
OperatingLeaseCost
4750000
CY2021Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
1713000
CY2020Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
1128000
us-gaap Operating Lease Payments
OperatingLeasePayments
3423000
us-gaap Operating Lease Payments
OperatingLeasePayments
3710000
CY2021Q3 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
166000
CY2020Q3 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
41190000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
17543000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
41571000
CY2021Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
8150000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
5087000
CY2021Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
57677000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
44460000
CY2020Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
49547000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
1848000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
8701000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
8482000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
8275000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
8355000
CY2021Q3 acad Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
44275000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
79936000
CY2021Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
14109000
CY2021Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
65827000
CY2021Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P9Y2M12D
CY2021Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.043
CY2020Q3 acad Capitalization Of Right Of Use Asset
CapitalizationOfRightOfUseAsset
40300000
CY2020Q3 acad Capitalization Of Lease Liability
CapitalizationOfLeaseLiability
40300000
CY2021Q3 acad Capitalization Of Right Of Use Asset
CapitalizationOfRightOfUseAsset
19200000
CY2021Q3 acad Capitalization Of Lease Liability
CapitalizationOfLeaseLiability
19200000

Files In Submission

Name View Source Status
0001564590-21-055347-index-headers.html Edgar Link pending
0001564590-21-055347-index.html Edgar Link pending
0001564590-21-055347.txt Edgar Link pending
0001564590-21-055347-xbrl.zip Edgar Link pending
acad-10q_20210930.htm Edgar Link pending
acad-10q_20210930_htm.xml Edgar Link completed
acad-20210930.xsd Edgar Link pending
acad-20210930_cal.xml Edgar Link unprocessable
acad-20210930_def.xml Edgar Link unprocessable
acad-20210930_lab.xml Edgar Link unprocessable
acad-20210930_pre.xml Edgar Link unprocessable
acad-ex311_8.htm Edgar Link pending
acad-ex321_6.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending